glp-1 agonist cardiovascular outcomes Summary of outcome trials with SGLT-2 inhibitors and GLP-1 receptor agonists (GLP-1RAs): cardiovascular

doi: 10.1038/nm.3997 149 NamKoongCKimMSJangBTLeeYHChoYMChoiHJ

Not necessarily

[DOI] [PubMed] [Google Scholar] 132.Melson E, Miras AD, Papamargaritis D

Vital Organ Support: These treatments help protect kidney function by reducing systemic inflammation and managing the internal pressure that can lead to chronic kidney disease

Additionally, tirzepatide did not attenuate the reduction of sleeping metabolic rate or 24-h sedentary energy expenditure in comparison to baseline (though not significantly different than placebo), but significantly increased fat oxidation and decreased carbohydrate and protein oxidation as compared to placebo [57]

A recent study suggests that the use of GLP-1 receptor agonists was associated with better outcomes compared with the use of DPP-4 inhibitors among patients with type 2 diabetes and advanced-stage chronic kidney disease